Profile data is unavailable for this security.
About the company
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
- Revenue in SEK (TTM)38.64m
- Net income in SEK-409.65m
- Incorporated1997
- Employees115.00
- LocationBioInvent International ABThe Gamma Building, Ideongatan 1LUND 223 70SwedenSWE
- Phone+46 462868550
- Fax+46 462110806
- Websitehttps://www.bioinvent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hVIVO PLC | 896.49m | 242.91m | 2.17bn | 274.00 | 9.07 | 4.05 | 7.54 | 2.42 | 0.0252 | 0.0252 | 0.0932 | 0.0565 | 0.9242 | -- | 4.25 | 234,974.50 | 25.04 | -0.643 | 46.68 | -1.29 | -- | -- | 27.10 | -0.765 | 1.60 | -- | 0.2530 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Devyser Diagnostics AB | 198.00m | -71.40m | 2.17bn | 119.00 | -- | 6.21 | -- | 10.96 | -4.37 | -4.37 | 12.12 | 21.17 | 0.4019 | 1.97 | 5.29 | 1,677,966.00 | -14.51 | -8.97 | -16.40 | -10.15 | 80.00 | 80.14 | -36.11 | -23.91 | 3.81 | -- | 0.1492 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Ose Immunotherapeutics SA | 966.72m | 533.30m | 2.19bn | 52.00 | 3.82 | 2.32 | 3.83 | 2.27 | 2.27 | 2.27 | 4.10 | 3.74 | 0.7541 | -- | 32.09 | 1,517,127.00 | 41.60 | -17.17 | 49.66 | -20.55 | -- | -- | 55.17 | -94.71 | -- | 9.24 | 0.3502 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Sensorion SA | 0.00 | -274.24m | 2.30bn | 61.00 | -- | 2.38 | -- | -- | -0.1048 | -0.1048 | 0.00 | 0.2777 | 0.00 | -- | -- | 0.00 | -36.68 | -35.12 | -47.21 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0274 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
| 4Basebio PLC | 8.30m | -136.99m | 2.32bn | -- | -- | -- | -- | 279.43 | -0.7843 | -0.7843 | 0.0476 | -0.4075 | 0.0508 | 0.6453 | 10.64 | -- | -83.78 | -- | -97.43 | -- | 69.63 | -- | -1,650.67 | -- | 2.53 | -18.44 | 1.51 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| Genfit SA | 973.20m | 258.02m | 2.33bn | 169.00 | 11.81 | 2.06 | 8.44 | 2.39 | 0.3404 | 0.3404 | 1.53 | 1.95 | 0.4322 | 543.50 | 2.61 | 528,308.20 | 11.46 | -12.57 | 14.53 | -15.30 | 97.41 | 94.96 | 26.51 | -76.23 | 3.74 | 9.33 | 0.4105 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Avacta Group Plc | 314.96m | -360.46m | 2.39bn | 154.00 | -- | 3.49 | -- | 7.59 | -0.0867 | -0.0867 | 0.075 | 0.1334 | 0.2555 | 4.63 | 3.15 | 146,876.60 | -29.24 | -- | -61.16 | -- | 42.08 | -- | -114.45 | -- | 1.21 | -1.23 | 0.3875 | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| Molecular Partners AG | 98.07m | -718.83m | 2.42bn | 162.00 | -- | 1.03 | -- | 24.72 | -1.75 | -1.75 | 0.2386 | 4.69 | 0.0392 | -- | 3.22 | 46,797.62 | -28.73 | -11.83 | -30.81 | -14.69 | -- | 99.28 | -732.97 | -45.30 | -- | -- | 0.0192 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Inventiva SA | 180.93m | -1.21bn | 2.45bn | 123.00 | -- | -- | -- | 13.55 | -2.08 | -2.08 | 0.3104 | -1.51 | 0.2833 | -- | 10.30 | 139,437.50 | -185.05 | -54.30 | -839.50 | -69.98 | -- | -- | -653.15 | -669.97 | 0.586 | -12.21 | -- | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Selvita SA | 877.59m | 126.43m | 2.62bn | 382.00 | 20.72 | 3.11 | 10.18 | 2.98 | 2.58 | 2.58 | 17.93 | 17.22 | 0.5415 | 9.29 | 4.44 | 388,455.70 | 7.80 | -- | 9.35 | -- | 78.69 | -- | 14.41 | -- | 1.06 | -0.1509 | 0.4236 | -- | -3.48 | -- | 130.55 | -- | -- | -- |
| Ryvu Therapeutics SA | 169.69m | -277.76m | 2.67bn | 230.00 | -- | 5.64 | -- | 15.75 | -4.50 | -4.50 | 2.75 | 7.69 | 0.1509 | 9.59 | 3.83 | 276,600.00 | -24.71 | -21.88 | -30.79 | -25.20 | 64.35 | -6.28 | -163.69 | -284.20 | 3.01 | -2,498.26 | 0.3878 | -- | 20.32 | -9.50 | -9.94 | -- | 53.71 | -- |
| Bioventix PLC | 189.46m | 112.74m | 2.70bn | 17.00 | 24.27 | 16.13 | 23.59 | 14.23 | 1.53 | 1.53 | 2.57 | 2.30 | 1.01 | 1.57 | 2.26 | 800,387.60 | 59.95 | 58.33 | 67.24 | 63.62 | 93.20 | 93.09 | 59.51 | 64.12 | 7.07 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
| BioInvent International AB | 38.64m | -409.65m | 3.01bn | 115.00 | -- | 3.00 | -- | 77.92 | -6.23 | -6.23 | 0.5871 | 15.24 | 0.0301 | -- | 0.6849 | 348,072.10 | -31.87 | -17.50 | -33.70 | -18.64 | -- | -- | -1,060.29 | -131.63 | 13.16 | -- | 0.0167 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
| Eurobio Scientific SA | 1.67bn | 76.97m | 3.06bn | 137.00 | 40.99 | -- | 14.50 | 1.83 | 0.6282 | 0.6282 | 13.50 | -- | -- | -- | -- | 1,052,883.00 | -- | 16.91 | -- | 21.53 | 46.81 | 50.95 | 4.61 | 23.34 | -- | 5.62 | -- | 0.00 | -14.81 | 20.80 | -80.61 | -- | 20.02 | -- |
| Allergy Therapeutics plc | 768.61m | -559.98m | 3.45bn | 635.00 | -- | 66.96 | -- | 4.49 | -0.0107 | -0.0107 | 0.0137 | 0.0008 | 0.8389 | 2.09 | 7.40 | -- | -61.12 | -22.88 | -86.97 | -30.15 | 53.87 | 66.47 | -72.86 | -24.88 | 1.01 | -8.70 | 0.8931 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
| Valneva SE | 1.84bn | -85.94m | 3.84bn | 695.00 | -- | 1.31 | 7.63 | 2.09 | -0.057 | -0.057 | 1.13 | 1.56 | 0.3057 | 2.03 | 4.24 | 231,777.80 | -1.43 | -15.39 | -2.09 | -25.06 | 38.58 | 35.94 | -4.68 | -34.95 | 2.25 | 2.06 | 0.4806 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
Data as of Nov 22 2024. Currency figures normalised to BioInvent International AB's reporting currency: Swedish Krona SEK
34.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Dec 2023 | 10.13m | 15.39% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 5.08m | 7.71% |
| Fj�rde AP-fondenas of 30 Jun 2024 | 4.02m | 6.11% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 1.69m | 2.56% |
| E. �hman J :or Fonder ABas of 31 Aug 2024 | 622.60k | 0.95% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2024 | 450.00k | 0.68% |
| SEB Investment Management ABas of 31 Oct 2024 | 344.25k | 0.52% |
| Skandia Investment Management ABas of 30 Sep 2024 | 324.58k | 0.49% |
| FCG Fonder ABas of 31 Oct 2024 | 222.82k | 0.34% |
| Medical Strategy GmbHas of 31 Jul 2024 | 94.00k | 0.14% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
